BAM Dataset

Medical Research & Policy

Funded Once, Gone Forever: The Quiet Crisis of Expiring Scientific Data

Across American research institutions, datasets assembled over years or decades—and paid for by public dollars—are quietly disappearing due to storage costs, shifting institutional priorities, and the absence of binding preservation requirements. The consequences extend far beyond inconvenience: lost longitudinal records, vanished environmental baselines, and clinical trial data that cannot be independently verified. This article examines the structural failures driving scientific data expiratio

Sep 4, 2026

Agricultural Science

The Toll Gate Remains: Academic Publishers, Preprint Culture, and the Unfinished Business of Open Science

Despite the rapid expansion of preprint servers and a decade of open-access mandates from federal funding agencies, the major commercial academic publishers continue to extract substantial revenue from publicly funded research—often while publicly endorsing the principles of data transparency. An examination of the economics of scholarly publishing, combined with case studies from researchers who have deliberately routed around traditional journals, reveals a system in which structural incentive

Sep 4, 2026

Medical Research & Policy

Lost Before They Can Be Found: The Silent Erosion of Scientific Datasets After Publication

Millions of dollars in publicly funded research vanish quietly each year—not through fraud or negligence, but through the mundane failures of broken hyperlinks, expired hosting contracts, and researcher departures that leave datasets stranded. A growing body of evidence suggests the scientific community is losing data faster than it can be replaced, undermining the cumulative nature of empirical inquiry. Archivists, librarians, and open-data advocates are now racing to document the scale of this

Sep 4, 2026

Medical Research & Policy

Rewiring the Incentives: How a New Generation of Universities Is Making Data Sharing a Career Asset

Tenure committees have long rewarded publications in prestigious journals while treating the release of underlying data as an afterthought. A small but growing cohort of American universities is dismantling that framework, embedding data transparency directly into the criteria by which researchers are hired, promoted, and funded. The institutions pioneering this shift offer an early look at what open science looks like when it is structurally incentivized rather than merely encouraged.

Sep 4, 2026

Agricultural Science

Methodology Under Lock and Key: The Proprietary Protocols Undermining Environmental Science

Across the United States, critical decisions about air quality, water safety, and soil contamination are being made on the basis of environmental studies that independent scientists cannot fully scrutinize. When the methods used to collect and analyze environmental data remain proprietary, the scientific foundation beneath public health policy quietly erodes. This investigation examines the structural incentives keeping environmental monitoring methodology behind closed doors—and the researchers

Sep 4, 2026

Medical Research & Policy

Replication as Resistance: Independent Researchers Are Auditing Oncology Science — and Finding It Wants

A growing cohort of academic researchers and independent scientists is using publicly available datasets to reproduce proprietary cancer studies — and in doing so, surfacing errors, methodological inconsistencies, and overlooked findings that original publishers never corrected. The movement represents a fundamental challenge to the closed-access model that has long governed oncology research, and its results are beginning to influence how treatments are evaluated and approved.

Sep 4, 2026

Medical Research & Policy

Trained to Miss: How Rare Disease Patients Are Being Systematically Excluded From Medical AI

Machine learning models built on population-scale genomic datasets are producing diagnostic tools that work well for common conditions but fail patients with rare genetic disorders. The structural incentives that govern data contribution to open repositories help explain why this gap persists — and why the patients who most need AI-assisted diagnosis are the least likely to receive it.

Sep 4, 2026

Medical Research & Policy

Invisible Evidence: How Drug Approval Data Submitted to the FDA Disappears From Scientific Scrutiny

Pharmaceutical companies submit vast quantities of safety and efficacy data to the FDA as part of the drug approval process — data that shapes prescribing decisions for millions of Americans but remains largely shielded from independent scientific review. This analysis argues that the current framework represents a structural failure of public health governance and examines what genuine transparency reform would demand.

Sep 4, 2026

Medical Research & Policy

Taxpayer-Funded, Publicly Unavailable: The Institutional Barriers Keeping NIH Research Data Out of Reach

Billions of federal dollars flow annually into biomedical research, yet the datasets those dollars produce are routinely locked behind institutional firewalls and subscription barriers. This investigation examines the legal, financial, and cultural forces that sustain this paradox — and profiles the researchers and institutions working to dismantle it.

Sep 4, 2026

Medical Research & Policy

When the Black Box Wins: Algorithmic Secrecy and the Reproducibility Crisis Reshaping Academic Science

Closed-source machine learning models embedded in peer-reviewed research are quietly undermining the scientific community's ability to verify its own findings. As retracted papers mount and frustration grows, researchers and open-science advocates are demanding a fundamental reckoning with computational opacity. The stakes extend well beyond academia—when algorithms cannot be examined, the public cannot trust the conclusions they produce.

Sep 3, 2026

Medical Research & Policy

Fragmented by Design: How Siloed Oncology Data Is Slowing the Fight Against Cancer

Clinical trials for cancer therapies generate extraordinary volumes of patient data—yet most of it remains locked inside hospital networks, pharmaceutical archives, and private databases that rarely communicate with one another. Researchers attempting to identify drug interactions, treatment patterns, and survival predictors are working with incomplete pictures assembled from incompatible sources. A new generation of open-data advocates is fighting to change that, and early results suggest the s

Sep 3, 2026

Agricultural Science

From Soil to Satellite: How Public Climate Data Is Leveling the Playing Field for American Farmers

Publicly available climate datasets are transforming how farmers across the Midwest and Great Plains plan their seasons, respond to drought, and manage pest outbreaks. Once the exclusive domain of large agribusiness operations, sophisticated weather modeling tools are now accessible to independent growers through open-access repositories. The implications for food security and sustainable agriculture in the United States are substantial.

Sep 3, 2026

Medical Research & Policy

Broken Findings: Inside the Movement to Rebuild American Medical Research on a Foundation of Transparent Data

A significant proportion of high-profile medical studies published in the United States cannot be reproduced by independent researchers — a systemic failure with profound consequences for patients, clinicians, and public trust in science. Open-access datasets and transparent research methodologies are emerging as the most credible structural solution to this crisis. This investigation examines why reproducibility collapsed, what it costs, and how institutions are beginning to rebuild.

Sep 3, 2026